



KAISER PERMANENTE[®]

Mid-Atlantic States

Surgical Treatment for Lymphedema and Lipedema

Medical Coverage Policy

UTILIZATION * ALERT*

- Prior to use of this MCP (Medical Coverage Policy) for evaluation of medical necessity, benefit coverage MUST be verified in the member's EOC (Evidence of Coverage) or benefit document.
- CMS (Center for Medicare Services) does not have national coverage determination on this topic. This policy serves as guidance for the medical necessity of lymphedema and lipedema surgical treatments for Medicare members

I. Procedure: Surgical Treatment for Lymphedema and Lipedema

II. Specialties: Surgery, Plastic Surgery, Lymphology, Dermatology, Wound Care

III. Clinical Indications for Referral

A. Lymphedema Surgical Treatment

Tumescent liposuction or water jet-assisted liposuction is considered medically necessary for the treatment of lymphedema when **ALL** the following criteria are met:

1. Patient has a confirmed diagnosis of lymphedema, specifically, signs and symptoms consistent with lymphedema as determined by a certified lymphedema therapist and a diagnosis of stage \geq II lymphedema (ISL) (see Table 1);
2. Required photograph of affected extremities accompanying request for treatment is consistent with the diagnosis of lymphedema; and
3. Significant functional impairment such as difficulty with mobility or performing activities of daily living (ADL) or medical complication (such as recurrent cellulitis); and
4. Documented history of uncontrolled or inadequate lymphedema control after exhausting a course of complex decongestive physiotherapy (CDP) or manual lymphoid drainage and compression therapy, for at least 3 consecutive months; and
5. The plan of care following surgery includes compression garment to maintain the benefits of surgery.

Table 1. International Society of Lymphology (ISL) scale for staging Lymphedema¹

1 | Page

¹ The diagnosis and treatment of Peripheral Lymphedema: 2020 Consensus document of the International Society of Lymphology, " *Lymphology* 53(1), p.3-19.

² Herbst K. L. (2012). Rare adipose disorders (RADs) masquerading as obesity. *Acta pharmacologica Sinica*, 33(2), 155–172.



KAISER PERMANENTE®

Mid-Atlantic States

Surgical Treatment for Lymphedema and Lipedema

Medical Coverage Policy

Stage	Description
Stage 0: Latent or Subclinical	<ul style="list-style-type: none"> ▪ Impaired lymphatic transport ▪ No evidence of swelling/edema, subtle changes in tissue fluid/composition ▪ Changes in subjective symptoms ▪ May last months or years before progression
Stage I Spontaneously Reversible or Mild	<ul style="list-style-type: none"> ▪ Early accumulation of protein-rich fluid ▪ Pitting edema, no evidence of dermal fibrosis ▪ Subsides with elevation
Stage II Spontaneously Irreversible or Moderate	<ul style="list-style-type: none"> ▪ Accumulation of protein-rich fluid ▪ Pitting edema may progress to non-pitting as excess fat and fibrosis develop ▪ Does not resolve with elevation alone
Stage III Lymphostatic Elephantiasis or Severe	<ul style="list-style-type: none"> ▪ Non-pitting edema ▪ Significant fibrosis ▪ Trophic skin changes such as fat deposits, acanthosis, and warty overgrowths

B. Lipedema Surgical Treatment

Tumescent liposuction or water jet-assisted liposuction is considered medically necessary for the treatment of lipedema when **ALL** the following criteria are met:

1. The patient has a confirmed diagnosis of lipedema based **ALL** the following findings except those noted in section III B, #1, f-h:
 - a. Pain, tenderness, and hypersensitivity in lipedema affected areas; and
 - b. Easy bruising or bruising without apparent cause in lipedema affected areas; and
 - c. Thickened subcutaneous fat in the affected extremities (legs, thighs, hips, or buttocks, or occasionally arms) bilaterally and symmetrically; and
 - d. Nodularity of fat deposits in lipedema affected areas (dimpled or orange-peel texture); and
 - e. Non-pitting edema in the affected area unless the member has co-existing lymphedema; and
 - f. Stemmer sign is negative (the folds of skin can be pinched and lifted at the base of the second toe or at the base of the middle finger) unless the member has comorbid lymphedema; and
 - g. Disproportionate fat distribution: for example, the lower body is disproportionately large

¹ The diagnosis and treatment of Peripheral Lymphedema: 2020 Consensus document of the International Society of Lymphology, " *Lymphology* 53(1), p.3-19.

² Herbst K. L. (2012). Rare adipose disorders (RADs) masquerading as obesity. *Acta pharmacologica Sinica*, 33(2), 155–172.



KAISER PERMANENTE[®]

Mid-Atlantic States

Surgical Treatment for Lymphedema and Lipedema

Medical Coverage Policy


- compared to the upper body. This requirement can be waived for those who meet the other listed criteria as a considerable proportion of individuals with lipedema may not have disproportionate fat distribution particularly in the early stage of the disease; and
- h. Evidence of "cuffing" (also called "braceletting" or "inverse shouldering"). Note: This criterion can be waived for individuals who meet the other listed criteria or have coexisting lymphedema as some individuals with lipedema may not exhibit cuffing or shouldering.
2. Documentation of significant functional impairment evidenced by difficulty with ambulation and mobility or performing activities of daily living or medical complication (such as recurrent cellulitis); and
 3. Lack of effect on lipedema affected areas following weight loss; and
 4. Limb elevation does not result in reduction of swelling on lipedema affected areas; and
 5. Documented history of inadequate or unsuccessful response to conservative (non-surgical) lipedema management, requiring documentation of adherence to a minimum of three consecutive months of treatment.; and
 6. The post-operative plan of care includes patient compliance to compression therapy to maintain the benefits of surgery.

Table 1. Stages of Lipedema by Dr. Wilfried Schmeller and Dr. Karen Herbst ¹.

Stages of Lipedema	Description
Stage 1	<ul style="list-style-type: none"> ▪ Even smooth skin surface with enlarged subcutaneous fat tissue ▪ Fat buildup around pelvis, buttocks, and hips. ▪ Fat buildup from buttocks to knees, with folds of fat around the inner side of the knee. ▪ Fat buildup from buttocks to ankles
Stage 2	<ul style="list-style-type: none"> ▪ Uneven skin pattern with the development of nodular elevations or mass-like appearance and indentations of subcutaneous fat, lipomas and/or angiolipomas ▪ Fat buildup around pelvis, buttocks, and hips. ▪ Fat buildup from buttocks to knees, with folds of fat around the inner side of the knee ▪ Fat buildup from buttocks to ankles.
Stage 3	<ul style="list-style-type: none"> ▪ Large deforming growths of nodular fat or hanging flaps of the thighs and around the knees causing severe contour deformity of the thighs and around the knee ▪ Large extrusions of fat tissue cause buildup from buttocks to knees, with

¹ The diagnosis and treatment of Peripheral Lymphedema: 2020 Consensus document of the International Society of Lymphology, " *Lymphology* 53(1), p.3-19.

² Herbst K. L. (2012). Rare adipose disorders (RADs) masquerading as obesity. *Acta pharmacologica Sinica*, 33(2), 155–172.

 KAISER PERMANENTE [®] Mid-Atlantic States	Surgical Treatment for Lymphedema and Lipedema Medical Coverage Policy
--	---

	folds of fat around the inner side of the knee. <ul style="list-style-type: none"> ▪ Large extrusions of fat tissue causing buildup from buttocks to ankles
Stage 4	<ul style="list-style-type: none"> ▪ Development of lipolymphedema where both lipedema and lymphedema are present in the body. This is characterized by large overhangs of tissue, dysfunctional lymphatics, and large extrusion of fat tissue on legs with progression to lipolymphedema

Table 2. Types of Lipedema

Types of Lipedema	Part of the body where adipose tissue builds up
Type 1	Pelvis to buttocks (saddle bag phenomenon)
Type 2	Buttocks to knees with formation of folds of fat around the inner side of the knee
Type 3	Buttocks to ankles
Type 4	Arms
Type 5	Isolated lower leg

IV. Exclusions

The following procedures are considered experimental, investigational, or unproven and therefore not medically necessary. Their effectiveness has not been established for the treatment of chronic lymphedema and lipedema.

A. Surgical Treatment

1. Lymphatic physiological microsurgical procedures such as:
 - a. Lymphatic-lymphatic bypass.
 - b. Lymphatico-venous anastomosis and lymphaticovenular anastomosis (also referred to as lympho-venous bypass).
 - c. Lymphatic-capsular-venous anastomosis; and
 - d. Autologous lympho-venous transplantation and vascularized lymph node transfer.
2. Minimally Invasive Tissue Excision with Possible Redundant Skin Excision (the MITESE Procedure).
3. Tissue transfer (such as omental flap or mesenteric flap);
4. Immediate lymphatic reconstruction;
5. Lymphedema direct excision (such as debulking, Charles procedure);
6. Reductive ablative techniques; and
7. Extracorporeal Shockwave Therapy (EST)

¹ The diagnosis and treatment of Peripheral Lymphedema: 2020 Consensus document of the International Society of Lymphology, " *Lymphology* 53(1), p.3-19.

² Herbst K. L. (2012). Rare adipose disorders (RADs) masquerading as obesity. *Acta pharmacologica Sinica*, 33(2), 155-172.



KAISER PERMANENTE[®]

Mid-Atlantic States

Surgical Treatment for Lymphedema and Lipedema

Medical Coverage Policy

B. Preventive surgical treatment

Lymphatic physiologic microsurgery performed during nodal dissection or breast reconstruction to prevent lymphedema (including, but not limited to Lymphatic Microsurgical Preventing Healing Approach) in individuals who are being treated for breast cancer are considered experimental and investigational; and

C. Reverse lymphatic mapping

Reverse lymphatic mapping used as part of lymphatic surgical or liposuction procedure is considered experimental and investigational

V. Description

“Cuffing” or “braceleting” (loss of ankle definition) refers to tissue enlargement that ends abruptly at ankles or wrists, sparing hands and feet.

“Stemmer sign” is a clinical finding to diagnose lymphedema. A positive finding would be to be able to pinch the folds of the patient’s skin in the dorsum of the foot or hand, associated with lymphedema.

Tumescent or micro-cannular liposuction is a technique that involves the injection of tumescent anesthetic (such as diluted lidocaine and epinephrine) and use of vibrating micro-cannula associated with power-assisted liposuction to remove adipose tissues.

Water jet-assisted liposuction is a method of liposuction that uses a pressurized stream of saline to dislodge the fat and more gently loosen and remove the fat cells to treat lipedema.

References

1. Herbst K. L. (2012). Rare adipose disorders (RADs) masquerading as obesity. *Acta pharmacologica Sinica*, 33(2), 155–172. <https://doi.org/10.1038/aps.2011.153>
2. (2020) International Society of Lymphology Executive Committee. “The diagnosis and treatment of Peripheral Lymphedema: 2020 Concensus document of the International Society of Lymphology,” *Lymphology* 53(1), p.3-19. PMID 32521126.doi: <https://doi.org/10.2458/lymph.4649> Accessed 03/28/2022.
3. Maastricht University Medical Center and ZonMw: The Netherlands Organization for Health Research and Development. Improving Quality of Survivorship for Breast Cancer-related Lymphedema by Lymphaticovenous Anastomosis: A Randomized Controlled Trial. Start Date: January 2019 Completion Date: Aug 2022 . Clinical Trial Identifier NCT 02790021. Accessed: 03/28/2022 <https://www.clinicaltrials.gov/ct2/show/NCT02790021?term=NCT02790021&rank=1>

¹ The diagnosis and treatment of Peripheral Lymphedema: 2020 Concensus document of the International Society of Lymphology, ” *Lymphology* 53(1), p.3-19.

² Herbst K. L. (2012). Rare adipose disorders (RADs) masquerading as obesity. *Acta pharmacologica Sinica*, 33(2), 155–172.



KAISER PERMANENTE[®]

Mid-Atlantic States

Surgical Treatment for Lymphedema and Lipedema

Medical Coverage Policy

4. M.D. Anderson Cancer Center and National Cancer Institute (NCI). Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients with Inflammatory or Locally Advanced Non-inflammatory Breast Cancer. Start Date: August 2018 Completion Date: Dec 2020 Clinical Trial Identifier NCT 03941756. Accessed: 03/28/2022
<https://www.clinicaltrials.gov/ct2/show/NCT03941756?term=NCT03941756&draw=2&rank=1>
5. Mayo Clinic. Preventing Lymphedema in Axillary Lymph Node Dissection. Start Date: April 2018 - Completion Date: Feb 2023 Clinical Trial Identifier NCT 03428581. Accessed: 03/28/2022
<https://www.clinicaltrials.gov/ct2/show/NCT03428581?term=NCT03428581&rank=1>
6. Hautklinik Darmstadt and The Clinical Trials Centre Cologne. Multicenter, Controlled, Randomized, Investigator-blinded Clinical Study on Efficacy and Safety of Surgical Therapy of Lipedema Compared to Complex Physical Decongestive. Start Date: December 2020 Completion Date: Jul 2025 Clinical Trial Identifier NCT 04272827 . Accessed: 03/28/2022
<https://www.clinicaltrials.gov/ct2/show/NCT04272827?term=NCT04272827&draw=2&rank=1>
7. DiSipio, T., Rye, S., Newman, B., & Hayes, S. (2013). Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. *The Lancet. Oncology*, 14(6), 500–515. Accessed 03/28/2022. [https://doi.org/10.1016/S1470-2045\(13\)70076-7](https://doi.org/10.1016/S1470-2045(13)70076-7)
8. National Lymphedema Network Medical Advisory Committee. The Diagnosis and Treatment of Lymphedema. Position Statement of the National Lymphedema Network 2011. Accessed March 28, 2022. Accessed: 03/28/2022 <https://lymphnet.org/position-papers>
9. Peprah, K., & MacDougall, D. (2019). *Liposuction for the Treatment of Lipedema: A Review of Clinical Effectiveness and Guidelines*. Canadian Agency for Drugs and Technologies in Health. Accessed: 03/28/2022. <https://www.cadth.ca/liposuction-treatment-lipedema-review-clinical-effectiveness-and-guidelines>
10. Austrian Academy of Cosmetic Surgery and Aesthetic Medicine (AACMS) and the International Society for Dermatologic Surgery (ISDS): Prevention of Progression of Lipedema With Liposuction Using Tumescant Local Anesthesia: Dermatologic surgery: official publication for American Society for Dermatologic Surgery [et al.], 46(2), 220–228. Accessed: 03/28/2022 <https://doi.org/10.1097/DSS.0000000000002019> , <https://pubmed.ncbi.nlm.nih.gov/31356433/>
11. National Institute for Health and Care Excellence (NICE). Liposuction for chronic lymphoedema. [IPG588]. 2017; <https://www.nice.org.uk/guidance/IPG588>. Accessed 03/28/2022
12. Premera Blue Cross Medical Policy Reference no. 7.01.567 Surgical Treatments for Lymphedema and Lipedema Effective date: January 2022. <https://www.premera.com/medicalpolicies/7.01.567.pdf>
13. Dadras, M., Mallinger, P. J., Corterier, C. C., Theodosiadi, S., & Ghods, M. (2017). Liposuction in the Treatment of Lipedema: A Longitudinal Study. *Archives of plastic surgery*, 44(4), 324–331.
<https://doi.org/10.5999/aps.2017.44.4.324>
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533060/pdf/aps-2017-44-4-324.pdf>

¹ The diagnosis and treatment of Peripheral Lymphedema: 2020 Consensus document of the International Society of Lymphology, ” *Lymphology* 53(1), p.3-19.

² Herbst K. L. (2012). Rare adipose disorders (RADs) masquerading as obesity. *Acta pharmacologica Sinica*, 33(2), 155–172.



KAISER PERMANENTE®

Mid-Atlantic States


Surgical Treatment for Lymphedema and Lipedema

Medical Coverage Policy

14. Cau, N., Cimolin, V., Aspesi, V., Galli, M., Postiglione, F., Todisco, A., Tacchini, E., Darno, D., & Capodaglio, P. (2019). Preliminary evidence of effectiveness of TECAR in Lymphedema. *Lymphology*, 52(1), 35–43. Accessed: 03/28/2022 <https://pubmed.ncbi.nlm.nih.gov/31119913/>
15. Herbst, K et al... Lipedema Fat and Signs and Symptoms of Illness, Increase with Advancing Stage. *IMedPub Journals. Archives of Medicine* 2015 Vol. 7 No. 4:10. Accessed: 03/29/2022 <https://www.lipoedema.co.uk/wp-content/uploads/2016/01/lipedema-fat-and-signs-and-symptoms-of-illness-increase-with-advancing-stage.pdf>
16. Van de Pas, C. B., Boonen, R. S., Stevens, S., Willemsen, S., Valkema, R., & Neumann, M. (2020). Does tumescent liposuction damage the lymph vessels in lipoedema patients?. *Phlebology*, 35(4), 231–236. <https://doi.org/10.1177/0268355519885217>
17. Ciudad, P., Sabbagh, M. D., Agko, M., Huang, T., Manrique, O. J., L, C. R., Reynaga, C., Delgado, R., Maruccia, M., & Chen, H. C. (2019). Surgical Management of Lower Extremity Lymphedema: A Comprehensive Review. *Indian journal of plastic surgery: official publication of the Association of Plastic Surgeons of India*, 52(1), 81–92. <https://doi.org/10.1055/s-0039-1688537>
18. Winters, H., Tielemans, H., Hameeteman, M., Paulus, V., Beurskens, C. H., Slater, N. J., & Ulrich, D. (2017). The efficacy of lymphaticovenular anastomosis in breast cancer-related lymphedema. *Breast cancer research and treatment*, 165(2), 321–327. <https://doi.org/10.1007/s10549-017-4335-0>
19. Chen, S. H., Cem Yildirim, M. E., Mousavi, S. A., & Chen, H. C. (2021). Long-term functional outcomes upon application of split-thickness skin graft around major joints in HCC (Hung-Chi Chen)-modified Charles' procedure for advanced lymphedema. *Asian journal of surgery*, 44(1), 169–173. <https://doi.org/10.1016/j.asjsur.2020.05.001>
20. Greene, A. K., & Goss, J. A. (2018). Diagnosis and Staging of Lymphedema. *Seminars in plastic surgery*, 32(1), 12–16. <https://doi.org/10.1055/s-0038-1635117>
21. Kruppa, P., Georgiou, I., Schmidt, J., Infanger, M., & Ghods, M. (2022). A 10-Year Retrospective before-and-after Study of Lipedema Surgery: Patient-Reported Lipedema-Associated Symptom Improvement after Multistage Liposuction. *Plastic and reconstructive surgery*, 149(3), 529e–541e. <https://doi.org/10.1097/PRS.00000000000008880>
22. National Institute for Health and Care Excellence (NICE). NICE guidelines [IPG721]. Liposuction for chronic lipoedema. March 2022. <https://www.nice.org.uk/guidance/ipg721>
23. Wounds UK. Best Practice Guidelines: The Management of Lipoedema. London: Wounds UK, 2017
24. Executive Committee of the International Society of Lymphology (2020). The diagnosis and treatment of peripheral lymphedema: 2020 Consensus Document of the International Society of Lymphology. *Lymphology*, 53(1), 3–19.
25. Wijaya, W. A., Peng, J., He, Y., Chen, J., & Cen, Y. (2020). Clinical application of axillary reverse mapping in patients with breast cancer: A systematic review and meta-analysis. *Breast (Edinburgh, Scotland)*, 53, 189–200. <https://doi.org/10.1016/j.breast.2020.08.007>

¹ The diagnosis and treatment of Peripheral Lymphedema: 2020 Consensus document of the International Society of Lymphology, " *Lymphology* 53(1), p.3-19.

² Herbst K. L. (2012). Rare adipose disorders (RADs) masquerading as obesity. *Acta pharmacologica Sinica*, 33(2), 155–172.

 KAISER PERMANENTE [®] Mid-Atlantic States	Surgical Treatment for Lymphedema and Lipedema Medical Coverage Policy
---	---

26. Finnane, A., Janda, M., & Hayes, S. C. (2015). Review of the evidence of lymphedema treatment effect. *American journal of physical medicine & rehabilitation*, 94(6), 483–498. <https://doi.org/10.1097/PHM.0000000000000246>
27. van Gent, W. B., Catarinella, F. S., Lam, Y. L., Nieman, F. H., Toonder, I. M., van der Ham, A. C., & Wittens, C. H. (2015). Conservative versus surgical treatment of venous leg ulcers: 10-year follow up of a randomized, multicenter trial. *Phlebology*, 30(1 Suppl), 35–41. <https://doi.org/10.1177/0268355514568848>

Approval History

Effective June 01, 2016, state filing is no longer required per Maryland House Bill [HB 798](#) – Health Insurance – Reporting

Date approved by RUMC	Date of Implementation
05/25/2022	05/25/2022
05/29/2023	05/29/2023
04/25/2024	04/25/2024

*The Regional Utilization Management Committee received delegated authority in 2011 to review and approve designated Utilization Management and Medical Coverage Policies by the Regional Quality Improvement Committee.

Note: Kaiser Permanente Mid-Atlantic States (KPMAS) include referral and authorization criteria to support primary care and specialty care practitioners, as appropriate, in caring for members with selected conditions. Whenever possible, Medical Coverage Policies are evidence-based and may also include expert opinion. Medical Coverage Policies are not intended or designed as a substitute for the reasonable exercise of independent clinical judgment by a practitioner in any particular set of circumstances for an individual member.

©2024, Kaiser Foundation Health Plan of the Mid-Atlantic States, Inc.
 ©2024 Mid-Atlantic Permanente Medical Group, P.C.

¹ The diagnosis and treatment of Peripheral Lymphedema: 2020 Consensus document of the International Society of Lymphology, ” *Lymphology* 53(1), p.3-19.

² Herbst K. L. (2012). Rare adipose disorders (RADs) masquerading as obesity. *Acta pharmacologica Sinica*, 33(2), 155–172.